p53: It has it all, but will it make it to the clinic as a marker in bladder cancer?

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5341-5344

  Real, Francisco X ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; APOPTOSIS; BLADDER CANCER; CANCER GROWTH; CELL CYCLE ARREST; CELL TYPE; DNA BINDING; EDITORIAL; FAMILIAL CANCER; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC MUTATION; TUMOR GENE; WILD TYPE;

GENES, P53; HUMANS; MUTATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 36849043021     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1904     Document Type: Editorial

References (33)

1. Eliyahu D, Raz A, Gruss P, et al: Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646-649, 1984
2. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989
3. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
4. Lang GA, Iwakuma T, Suh YA, et al: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872, 2004
5. Caulin C, Nguyen T, Lang GA, et al: An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117:1893-1901, 2007
6. Li Y, Prives C: Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26:2220-2225, 2007
7. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al: p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137, 2005
8. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408:307-310, 2000
9. Petitjean A, Achatz MIW, Borresen-Dale AL, et al: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165, 2007
10. Soussi T, Beroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233-240, 2001
11. Olivier M, Eeles R, Hollstein M, et al: The IARC TP53 Database: New online mutation analysis and recommendations to users. Hum Mutat 19:607-614, 2002
12. Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485, 1999
13. Weisz L, Oren M, Rotter V: Transcription regulation by mutant p53. Oncogene 26:2202-2211, 2007
14. Strano S, Dell'Orso S, Di Agostino S, et al: Mutant p53: An oncogenic transcription factor. Oncogene 26:2212-2219, 2007
15. Soussi T: p53 alterations in human cancer: More questions than answers. Oncogene 26:2145-2156, 2007
16. Malats N, Bustos A, Nascimento CM, et al: P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6:678-686, 2005
17. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited! J Pathol 172:1-4, 1994
18. Hernandez S, Lopez-Knowles E, Lloreta J, et al: FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 11:5444-5450, 2005
19. George B, Datar RH, Wu L, et al: p53 gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 25:5352-5358, 2007
20. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994
21. Kelsey KT, Hirao T, Schned A, et al: A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 90:1572-1576, 2004
22. López-Knowles E, Hernández S, Kogevinas M, et al: The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12:6029-6036, 2006
23. Cote RJ, Esrig D, Groshen S, et al: p53 and treatment of bladder cancer. Nature 385:123-125, 1997
24. Dyrskjot L, Thykjaer T, Kruhoffer M, et al: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33:90-96, 2003
25. Dyrskjot L, Zieger K, Kruhoffer M, et al: A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11:4029-4036, 2005
26. Dyrskjot L, Zieger K, Real FX, et al: Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 13:3545-3551, 2007
27. Olivier M, Langerod A, Carrieri P, et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167, 2006
28. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2:416-422, 2005
29. Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Quality of reporting of cancer prognostic marker studies: Association with reported prognostic effect. J Natl Cancer Inst 99:236-243, 2007
30. Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 92:434-444, 2005
31. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872, 2003
32. Altshuler D, Daly M: Guilt beyond a reasonable doubt. Nat Genet 39:813-815, 2007
33. NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, Manolio T, et al: Replicating genotype-phenotype associations. Nature 447:655-660, 2007